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Interest, support, dedication as well as a structured personal 
approach in these terms are absuletly necessary, but not 
always self-evident – they can be aqcuired and the path can 
be adjusted – to make a 'dream career’ not a ‚road less 
travelled’. 
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Defining one’s ‘dream’ career is challenging for any 
professional, however approaching your career trajectory in a 
‘smart’ fashion is prudent as a young RTT.  
In this presentation, the importance of self-awareness in 
building your career will be discussed.  This includes an 
ability to acknowledge your own strengths and limitations, an 
awareness of the impact of your interactions with others on 
your future, as well as an understanding of how you are 
perceived within your profession and in the wider field.  
The importance of a mentor will be discussed as their 
influence in the future direction of your career cannot be 
underestimated.  A mentor may have an extremely positive 
influence on your career path and does not necessarily have 
to be from the same professional field.  Often, an objective 
viewpoint on the progress of your career from outside the 
field can be most beneficial.   
Provision of quality care in radiotherapy is only possible 
through extensive collaboration and teamwork.  Finding your 
place in a team is critical to your future success and 
interestingly, sometimes the best place for you in a team 
may not necessarily be the one that you had initially 
anticipated.   
Finally, balancing the position of your career within your life 
is what will bring the ‘dream’ to your career.  
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Purpose/Objective: To assess outcomes and toxicity of 
intraoperative electron-beam radiation therapy (IOERT) in 
the management of pediatric ewing´s sarcoma (EWS) and 
rhabdomyosarcoma (RMS) patients. 
Materials and Methods: From June 1983 to September 2012, 
71 patients (aged <21 years) with a histologic diagnosis of 
primary or locally recurrent EWS (n=37) or RMS (n=34); 
undergoing conservative resection, IOERT (median dose 10 
Gy) with or whitout external beam radiation therapy (median 
dose 40 Gy) were considered eligible for this analysis. 
Results: After amedian follow-up of 72 months (range, 4-
310months), 10-year local control, disease-free survival, and 
overall survival was 74%, 57%, and 68%, respectively. Severe 
chronic toxicity (grade ≥ 3) ocurred in nine patients (13%).  
Conclusions: IOERT containing multimodality therapy for 
patients with pediatric sarcoma is well-tolerated, with high 
local control and acceptably low chronic toxicity rates. 
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Purpose/Objective: The goal of the present study was to 
analyze prognostic factors in patients treated with surgical 
resection, intraopera-tive electron-beam radiotherapy 
(IOERT) with and wthout external beam radiotherapy (EBRT) 
for local (loco-regional) oligo-recurrent sarcoma (ORS), 
gynecological (ORGC) or rectal cancer (ORRC).  
Materials and Methods: From January 1986 to December 
2012, 224 patients with locally oligo-recurrent cancer (ORGC, 
n=61; ORRC, n=60; ORS, n=103) underwent IOERT (12.5 Gy, 
range 10–15 Gy), and surgical resec-tion with or whotout 
EBRT (range 30.6–50.4 Gy). Survival outcomes were estimated 
using the Kaplan–Meier method, and risk fac-tors were 
identified by univariate and multi-variate analyses. 
Results: The median follow-up time was 55 months (range, 2-
189 months), and 5-year locoregional control (LRC) and 
overall survival (OS) rates were 60, 44 and 65%; and 52, 43, 
43% and 42 for ORS, ORRC and ORGC, respectively. On 
multivariate analysis, R1 resection, receiving EBRT at the 
time of recurrence and no tumor fragmentation retained 
significance with regard to LRC. 
Conclusions: This joint analysis revealed that surgical 
margin, tumor fragmentation and EBRT affect LRC. 
Intensified local treatment needs to be further tested in the 
context of more efficient concurrent, neoadjuvant, and 
adjuvant systemic therapy. 
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Purpose/Objective: Well-differentiated thyroid cancer 
patients have relatively good prognosis even if they had 
distant metastases and can be treated by surgery, external 
beam radiation therapy, radioactive iodines, and thyroid 
hormones, etc. Spinal cord compression caused by spinal 
metastases is normally considered to carry devastating 
prognosis both for quantity and quality. However, with the 
use of decompression surgery and IORT, the patient’s quality 
of life has improved and with the use of multimodal 
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treatment thereafter, their prognosis has been improving. We 
analyzed the results of our 18-year experience. 
Materials and Methods: Between 1993 and April 2011 48 
patients (68 times) were treated. Their age ranged from 46 
to 86 with a median of 64. There were 20 male patients and 
28 females. Seventeen patients were unable to walk before 
IORT, while the remaining 31 were ambulant. IORT was given 
with proper energy electron beam from posteriorly shielding 
the spinal cord with lead of proper thickness. The doses of 
IORT ranged from 16Gy to 26Gy with a median of 20Gy. Ten 
patients received IORT more than once (2 to 6 times). 
External beam radiation therapy was administered in 29 
patients, of which 1 received preoperatively (24Gy), 20 
received postoperatively (20~40Gy, median 35.5Gy). All 
patients received thyroid stimulating hormone suppression 
therapy. Radioactive iodines (Iodine-131) were administered 
in 29 patients. Median follow-up period was 33 months. 
Results: Among 17 patients who had been unable to walk 15 
became able to walk following IORT, while the remaining 2 
died soon after the treatment (response: not evaluable). 
Overall median survival time of overall patients was 38 
months. Three- and 5-year overall survival rates were 51% 
and 33%, respectively. Symptomatic recurrence was observed 
in 6 cases (14%).  
Conclusions: Well-differentiated thyroid cancer patients 
carried quite favorable prognoses considering their status 
prior to IORT. From our experience, aggressive treatment was 
justified since more than half of the patients survived 3 years 
and about one third of the patients survived 5 years. 
Furthermore, only small portion of the patients suffered from 
symptomatic recurrence. Our methods were very promising 
both for quantity and quality of life in the treatment of 
spinal metastases from well-differentiated thyroid cancer. 
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Purpose/Objective: Kyphoplasty combined with 
intraoperative radiotherapy (Kypho-IORT) is a novel 
treatment modality for patients with spinal metastases. The 
technical feasibility and the operation principle of this 
approach have been described. In this study we present the 
results of the conducted phase II dose escalation study (NCT 
01280032) and update the clinical data of a pilot phase. 
Materials and Methods: For Kypho-IORT the INTRABEAM 
system (Carl Zeiss Surgical, Oberkochen, Germany) with a 
specially designed applicator was used. In the phase II study 
three dose escalation levels were tested: 8 Gy in 8 mm, 8 Gy 
in 10mm and 8 Gy in 13 mm depth from the isocenter of the 
radiation source. Inclusion criteria were age of ≥ 50 years, 
Karnofsky-Index of ≥ 60% and histologically or radiologically 
documented spinal metastases (≤ 2cm) caudal the 3rd thoracic 
vertebra. Off-study patients were treated analogue the first 
two dose levels. 
Results: Overall 61 patients received a Kypho-IORT. 9 
patients were included in the phase II dose escalation study, 
the remaining 52 patients were treated off-study in a pilot 
phase. For the whole cohort the 3, 6 and 12 months overall 
survival was 76.9%, 64.0% and 48.4%. The 3, 6 and 12 months 
local progression free survival was 97.5%, 93.8% and 93.8%. 
There was a significantly pain reduction from median VAS 
5/10 before Kypho-IORT to median VAS 2/10 first day after 
Kypho-IORT (p<0.001). 3, 6 and 9 months after Kypho-IORT 
also a significantly pain reduction compared to the 
preoperative situation was seen in the entire cohort (n= 33, 
21, 18 patients, respectively; all p <0.005). For the on-study 
patients the 3, 6 and 12 months local PFS was 100%, 83.3% 
and 83.3%. The median pain improvement was also significant 
(VAS 4/10 preoperatively vs. VAS 1/10 postoperatively, 
p=0.018). For the off-study patients the 3, 6 and 12 months 
local PFS was 96.9% respectively. The median pain score 
significantly improved from VAS 5/10 before the procedure to 
VAS 2/10 at the first postoperative day (p<0.001). There 
were no dose-limiting toxicities in the three dose escalation 
levels. 
Conclusions: Kypho-IORT is an alternative therapy approach 
for patients with spinal metastases in the palliative 
treatment setting with good local tumor control and 
immediate and permanent pain relief without severe side 
effects. A dose of 8 Gy in 13 mm depths from the isocenter 
could be determined as a save maximally tolerated dose and 
will be consolidated in a phase III study.  
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Purpose/Objective: In 2009 we reported promising first 
results of a European pooled analysis which evaluated the use 
of intraoperative radiation therapy (IORT) in the treatment of 
soft tissue sarcomas. However, comparison of these results 
with non-IORT series seemed difficult, mainly because of the 
inclusion of grossly incomplete resected lesions, patients 
treated without additional external beam radiation therapy 
(EBRT) and comparatively short follow-up. Therefore we 
aimed to re-analyze our data limited to the patients who 
received IORT preceeded or followed by EBRT after gross 
total resection with extended follow-up.  
Materials and Methods: Three European expert centers 
participated in the current analysis. Patients with gross 
incomplete resection, missing documentation of EBRT or 
lesions outside the extremities were excluded, leaving 250 
patients for analysis. Individual patient and treatment 
characteristics including gender, age, disease situation, 
timing and dose of EBRT component, surgical procedure, 
resection margin, use of chemotherapy and IORT 
specifications as well as the onset of oncological events like 
local/distant recurrence or death and treatment related 
effects like severe toxicities and complications were fully re-
analyzed according to the patient's treatment and follow-up 
charts.  
Results: Overall results including Kaplan-Meier estimates for 
local control, distant control and overall survival will be 
